These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28771355)

  • 1. Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.
    Bech EM; Martos-Maldonado MC; Wismann P; Sørensen KK; van Witteloostuijn SB; Thygesen MB; Vrang N; Jelsing J; Pedersen SL; Jensen KJ
    J Med Chem; 2017 Sep; 60(17):7434-7446. PubMed ID: 28771355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-binding domain extends half-life of glucagon-like peptide-1.
    Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
    Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
    Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
    Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
    Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F
    Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
    Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
    Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
    Wismann P; Pedersen SL; Hansen G; Mannerstedt K; Pedersen PJ; Jeppesen PB; Vrang N; Fosgerau K; Jelsing J
    Physiol Behav; 2018 Aug; 192():72-81. PubMed ID: 29540315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
    Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
    Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
    Cai X; Sun L; Dai Y; Avraham Y; Liu C; Han J; Liu Y; Feng D; Huang W; Qian H
    Bioorg Med Chem; 2018 May; 26(9):2599-2609. PubMed ID: 29673717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives.
    Sun X; Zhang Z; Liu M; Zhang P; Nie L; Liu Y; Chen Y; Xu F; Liu Z; Zeng Y
    Biomed Pharmacother; 2022 Apr; 148():112722. PubMed ID: 35202915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoglycolipids for Prolonging the Effects of Peptides: Self-Assembling Glucagon-like Peptide 1 Analogues with Albumin Binding Properties and Potent in Vivo Efficacy.
    van Witteloostuijn SB; Mannerstedt K; Wismann P; Bech EM; Thygesen MB; Vrang N; Jelsing J; Jensen KJ; Pedersen SL
    Mol Pharm; 2017 Jan; 14(1):193-205. PubMed ID: 28005376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
    Lau J; Bloch P; Schäffer L; Pettersson I; Spetzler J; Kofoed J; Madsen K; Knudsen LB; McGuire J; Steensgaard DB; Strauss HM; Gram DX; Knudsen SM; Nielsen FS; Thygesen P; Reedtz-Runge S; Kruse T
    J Med Chem; 2015 Sep; 58(18):7370-80. PubMed ID: 26308095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged half-life of small-sized therapeutic protein using serum albumin-specific protein binder.
    Kim TY; Park JH; Shim HE; Choi DS; Lee DE; Song JJ; Kim HS
    J Control Release; 2019 Dec; 315():31-39. PubMed ID: 31654685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential.
    Han J; Chen X; Wang Y; Fei Y; Zhou F; Zhang Y; Liu L; Si P; Fu J
    Biochem Pharmacol; 2017 Oct; 142():155-167. PubMed ID: 28668697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
    Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
    Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
    Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
    Han J; Fu J; Yang Q; Zhou F; Chen X; Li C; Yin J
    Eur J Med Chem; 2020 Jul; 198():112389. PubMed ID: 32388115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.
    Reddiar SB; Abdallah M; Styles IK; Müllertz OO; Trevaskis NL
    Eur J Pharm Biopharm; 2024 Jul; 200():114339. PubMed ID: 38789061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity.
    Han J; Huang X; Sun L; Li Z; Qian H; Huang W
    Biochem Pharmacol; 2013 Jul; 86(2):297-308. PubMed ID: 23707756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
    Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M
    J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.